Surgeries & Interventions

Cryoablation as a First-Line AFib Therapy

For people with atrial fibrillation, cryoballoon catheter ablation (cryoablation) as a first-line treatment can halt disease progression and reduce long-term burden. 

Cryoablation involves using extreme cold to kill harmful tissue in the heart and is usually reserved for patients who don’t respond to antiarrhythmic drugs. 

The authors of this NEJM-published study argue that it may be better to start with cryoablation. While AFib begins as an isolated electrical disorder, each recurring incident can cause electrical and structural changes in the heart that can lead to longer-lasting events. In contrast to drug therapies, cryoablation directly targets and destroys the tissue that initiates and perpetuates AFib, and thus can lead to longer lasting results. 


In the study, 303 patients with AFib were randomized to receive either cryoablation or antiarrhythmic drugs. After three years, patients in the cryoablation group had greater improvements than those who received initial antiarrhythmic drug therapy. Early cryoablation was associated with…

  • Fewer episodes of persistent AFib (1.9% vs. 7.4%)
  • Less recurrence of atrial tachyarrhythmia (56.5% vs. 77.2%)
  • Fewer hospitalization events (5.2% vs. 16.8%)
  • Fewer adverse events (4.5% vs. 10.1%)
  • Improvements in quality of life

The Takeaway 

First-line cryoablation led to fewer episodes of persistent AFib, reduced arrhythmia recurrence, lower AFib burden, meaningful improvements in quality of life, lower rates of health care utilization, and lower rates of adverse events. In other words, cryoablation outperformed antiarrhythmic drugs as a first-line defense against AFib. 

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Electrophysiology August 21, 2025

Conduction-System Pacing Succeeds at Treating AV Block August 21, 2025

Conduction-system pacing could be poised to reshape standard care for atrioventricular (AV) block patients after the randomized CSPACE trial demonstrated its significant benefits over traditional right ventricular septal pacing. Taking a closer look at CSP’s potential, the CSPACE trial enrolled 202 patients with AV block at two Australian hospitals, randomizing them to conduction-system pacing or […]

Cardiology Pharmaceuticals August 18, 2025

Rivaroxaban Monotherapy Could Be Better for CAD + AFib August 18, 2025

New analysis from the AFIRE trial suggests rivaroxaban monotherapy might be emerging as a preferred antithrombotic strategy for patients with AFib and stable coronary artery disease, especially in older age groups. The Post Hoc AFIRE Analysis examined 2,215 Japanese patients with AFib and stable CAD, stratifying them into four age groups (<70, 70-74, 75-79, and […]

Surgeries & Interventions August 14, 2025

TEER Could Save Lives in AFMR Patients August 14, 2025

Shedding light on a new treatment for an understudied condition, data published in EHJ suggests that transcatheter edge-to-edge repair (TEER) delivers significant survival advantages in patients with atrial functional mitral regurgitation (FMR). The new OCEAN-Mitral/REVEAL-AFMR Analysis compared 441 TEER-treated patients against 640 medically managed controls with moderate or severe atrial FMR, stating a solid case […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!